Vaderis Therapeutics has raised $152M and started a global Phase 3 trial of engasertib in patients with hereditary hemorrhagic telangiectasia.

$152M financing funds pivotal development

Vaderis Therapeutics has raised $152 million in a Series B financing alongside the start of a global Phase 3 clinical trial evaluating engasertib in hereditary hemorrhagic telangiectasia (HHT).

The financing was co-led by Life Sciences at Goldman Sachs Alternatives and TCGX, with participation from Omega Funds, EQT Life Sciences, Perceptive Advisors, Kalehua Capital and existing investors Medicxi and Droia.

Vaderis said the proceeds are expected to fund its operations through planned regulatory submissions and potential US regulatory approval of engasertib.

The financing comes as the company moves the investigational treatment into pivotal-stage development for HHT, a rare genetic vascular disorder characterised by abnormal blood vessel formation and recurrent bleeding.

Engasertib is an oral allosteric inhibitor of AKT1/2 designed to target signalling pathways involved in the formation of vascular malformations.

The treatment has not been approved for any indication in any country.

Global Phase 3 HEROIC study

The HEROIC study is a randomised, double-blind, placebo-controlled Phase 3 trial evaluating once-daily oral engasertib in patients with moderate-to-severe HHT.

The global study is expected to enrol patients at sites across North America, South America and Europe.

The trial follows earlier proof-of-concept and long-term extension studies of engasertib. Vaderis said those data showed clinically meaningful and sustained improvements across several measures of HHT disease.

The company said the earlier findings provided the basis for advancing engasertib into pivotal development.

HHT affects blood vessels and can cause recurrent nosebleeds, anaemia and arteriovenous malformations (AVMs) in organs including the lungs, liver and brain.

Despite the disease burden, there are currently no approved therapies specifically for HHT.

Hanny Al-Samkari, principal investigator of the HEROIC study and associate professor of medicine at Harvard Medical School, said the Phase 3 trial would test the earlier findings in a larger patient population.

“HHT remains a serious, lifelong disease that places a substantial burden on patients, yet there are still no approved therapies,” Al-Samkari said.

Engasertib targets vascular signalling

Engasertib, also known as VAD044, is designed to inhibit AKT1/2, components of a signalling pathway involved in vascular biology.

Vaderis is investigating whether modifying this pathway can address abnormalities in blood vessel development that contribute to HHT.

The disease is caused by genetic changes affecting blood vessel formation and is estimated to affect around one in 3,800 people.

Patients can experience recurrent severe epistaxis, or nosebleeds, as well as gastrointestinal bleeding, anaemia and complications associated with visceral AVMs.

Azmi Nabulsi, president and CEO of Vaderis Therapeutics, said the start of the Phase 3 programme represented a new stage in the development of engasertib.

“Closing this financing and initiating HEROIC as the first Phase 3 study utilizing a molecule specifically developed for HHT marks an exciting new chapter,” Nabulsi said.

The company is now conducting the HEROIC study to establish the efficacy and safety of engasertib in a larger patient population.

The Phase 3 programme follows publication of earlier engasertib findings in The New England Journal of Medicine, which Vaderis said demonstrated improvements across multiple measures of HHT.

The results from HEROIC will be important in determining whether those earlier findings can be confirmed in a pivotal trial and support future regulatory applications.